Literature DB >> 12902562

Percutaneous radiofrequency ablation of lung tumors in a large animal model.

Kamran Ahrar1, Roger E Price, Michael J Wallace, David C Madoff, Sanjay Gupta, Frank A Morello, Kenneth C Wright.   

Abstract

PURPOSE: Percutaneous radiofrequency ablation (RFA) is accepted therapy for liver tumors in the appropriate clinical setting, but its use in lung neoplasms remains investigational. We undertook this study to evaluate the feasibility and immediate effectiveness of RFA for treatment of both solitary pulmonary nodules and clusters of lung tumors in a large animal model.
MATERIALS AND METHODS: Percutaneous RFA of 14 lung tumors in five dogs was performed under CT guidance. Animals were euthanatized 8-48 hours after the procedure. The lungs and adjacent structures were harvested for gross and histopathologic evaluation.
RESULTS: Five solitary pulmonary nodules (range, 17-26 mm) and three clusters of three nodules each (range, 7-17 mm per nodule) were treated with RFA. All ablations were technically successful. Perilesional ground-glass opacity and small asymptomatic pneumothoraces (n = 4) were visualized during the RFA sessions. One dog developed a large pneumothorax treated with tube thoracostomy but was euthanatized 8 hours post-RFA for persistent pneumothorax and continued breathing difficulty. Follow-up CT 48 hours post-RFA revealed opacification of the whole lung segment. Gross and histopathologic evaluation showed complete thermal coagulation necrosis of all treated lesions without evidence of any viable tumor. The region of thermal coagulation necrosis typically extended to the lung surface. Small regions of pulmonary hemorrhage and congestion often surrounded the areas of coagulation necrosis.
CONCLUSIONS: RFA can be used to treat both solitary pulmonary nodules and clusters of tumor nodules in the canine lung tumor model. This model may be useful for development of specific RFA protocols for human lung tumors.

Entities:  

Mesh:

Year:  2003        PMID: 12902562     DOI: 10.1097/01.rvi.0000083300.97226.81

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  5 in total

1.  [Radiofrequency ablation of malignant lung tumours. Judicious approach?].

Authors:  W Jungraithmayr; O Schäfer; E Stoelben; J Hasse; B Passlick
Journal:  Chirurg       Date:  2005-09       Impact factor: 0.955

2.  Effects and risks of radiofrequency ablation on the pulmonary tissue and vascular system: a preliminary histological study.

Authors:  Eiji Ogawa; Tatsuo Fukuse; Yoshinobu Toda; Hirokazu Kotani; Hiromi Wada; Toshiaki Manabe
Journal:  Surg Today       Date:  2008-04-30       Impact factor: 2.549

3.  Establishment of a large animal model for research on transbronchial arterial intervention for lung cancer.

Authors:  Zhichao Sun; Xiao An; Hongchao Liu; Weihua Dong; Xiangsheng Xiao
Journal:  Diagn Interv Radiol       Date:  2021-07       Impact factor: 2.630

Review 4.  CT-guided radiofrequency ablation for lung cancer.

Authors:  Toshiyuki Matsuoka; Tomohisa Okuma
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

Review 5.  Radiofrequency ablation of pulmonary tumours: current status.

Authors:  Karin Steinke
Journal:  Cancer Imaging       Date:  2008-03-03       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.